LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against United States Steel Corporation (“U.S. Steel” or the “Company”) (NYSE: X) concerning possible violations of federal securities laws between November 1, 2016 and April 25, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, U.S. Steel issued materially false and/or misleading statements and/or failed to disclose: that while the Company was implementing its Carnegie Way program, it focused on cutting costs and not making investments necessary to position U.S. Steel so that it could respond to improved market conditions; that the Company’s failure to invest in improving capital assets during the industry downturn, in order to report apparent financial improvements, meant that U.S. Steel had higher production costs than its competitors, even in the face of improved pricing, which would negatively impact its financial results; and that U.S. Steel was forestalling expensive capital equipment upgrades in order to boost its short-term financial results at the expense of long-term financial performance, leaving U.S. Steel in need of accelerated, costly equipment upgrades that would leave the Company years away from generating improved financial performance. Following this news, U.S. Steel’s stock price declined materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 464342

LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against U.S. Physical Therapy, Inc. (“U.S. Physical Therapy” or the “Company”) (NYSE: USPH) for possible violations of federal securities laws between May 8, 2014 and March 16, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the May
30, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, U.S. Physical Therapy and certain of its officers and/or directors violated federal securities laws. On March 16, 2017, the Company disclosed that it incorrectly accounted for redeemable non-controlling interests of acquired partnerships. The Company stated that, as a result of accounting errors, it would report a material weakness in its internal controls over financial reporting and restate previously-issued financial statements; and that consolidated reports for the years ended December 31, 2015 and 2014, and all quarters within 2014 and 2015, and the first three quarters of 2016 should no longer be relied upon. Following this news, U.S. Physical Therapy’s share price lowered materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 464341

IRVINE, CA / ACCESSWIRE / May 26, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against U.S. Concrete, Inc. (“U.S. Concrete” or the “Company”) (NASDAQ: USCR). Investors, who purchased or otherwise acquired the Company’s shares between March 6, 2015 and March 23, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the May 30, 2017 lead plaintiff motion deadline.

If you purchased U.S. Concrete shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, during the Class Period, U.S. Concrete made false and misleading statements and/or failed to disclose that the Company lacked effective internal controls over financial reporting. On March 24, 2017, U.S. Concrete filed a Current Report on Form 8-K with the SEC, announcing the resignation of its Chief Financial Officer, Joseph Tusa, and advising investors that the Company replaced its previous auditor, Grant Thornton LLP, with Ernst & Young LLP as its new public accounting firm. When this news was announced to the public, Company’s stock price dropped materially, which allegedly caused investors harm.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464340

LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Inventure Foods, Inc. (“Inventure” or the “Company”) (NASDAQ: SNAK) for possible violations of federal securities laws between March 3, 2016 and March 16, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the May 30, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Inventure made false and/or misleading statements and/or failed to disclose: that the Company lacked adequate internal controls over accounting and financial reporting; that Inventure’s statements of operations in its fiscal year 2015 results press release contained incorrect figures; and that as a result of the above, the Company’s statements concerning its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On March 9, 2017, Inventure revealed that it would delay its annual filing on Form 10-K for its fiscal year ended December 31, 2016 and that it expected to file a notification of late filing on Form 12b-25 with the SEC to obtain a 15-day extension of the filing deadline for the Form 10-K. On March 16, 2017, the Company filed a notice with the SEC revealing that it would delay its 2016 fiscal year annual report. The Company also said that it believes its statements of operations contained in the annual report “will differ materially” from those reported for its fourth quarter and fiscal year 2015. Following the release of this news, Inventure’s stock price dropped significantly, which harmed investors according to the Complaint.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 464339

NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Bexil Corporation (OTC PINK: BXLC) today reported its financial results for the first quarter ended March 31, 2017. Bexil recorded net income attributable to Bexil shareholders of $0.34 million or $0.35 per share for the three months ended March 31, 2017, compared to net income attributable to Bexil shareholders of $0.26 million, or $0.27 per share, for the three months ended March 31, 2016.

The Company’s book value per share attributable to Bexil shareholders at March 31, 2017 was $20.21, based on shareholders’ equity attributable to Bexil shareholders of $17.9 million and 884,878 shares issued and outstanding.

The Company’s unaudited balance sheet, statements of comprehensive loss, and statements of cash flows as of and for the three months ended March 31, 2017 are appended to the copy of this press release on www.Bexil.com.

About Bexil Corporation

Bexil is a holding company engaged through subsidiaries in investment management and securities trading. To learn more about Bexil, including Rule 15c2-11 information, please visit www.Bexil.com.

Safe Harbor Note

This release contains certain “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Bexil, which may cause the Company’s actual results to be materially different from those expressed or implied by such statements. Investors should carefully consider the risks, uncertainties and other factors, together with all of the other information included in the Company’s Annual Report, at http://www.bexil.com/cautionary-language.html, and similar information. The forward-looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor’s understanding of the Company’s underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders’ equity attributable to Bexil shareholders divided by currently issued and outstanding shares.

Contact:

Thomas O’Malley
Chief Financial Officer
1-212-785-0900, ext. 267
tomalley@bexil.com
www.Bexil.com

SOURCE: Bexil Corporation

ReleaseID: 464336

NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Bexil Corporation (OTC PINK: BXLC) today reported its financial results for the year ended December 31, 2016. Bexil recorded net income attributable to Bexil shareholders of $0.95 million, or $0.97 per share, for the year ended December 31, 2016, compared to a net loss attributable to Bexil shareholders of $1.66 million, or $1.69, including $0.6 million, or $0.59 per share income from discontinued operations per share for the year ended December 31, 2015.

The Company’s book value per share attributable to Bexil shareholders at December 31, 2016 was $18.64, based on shareholders’ equity attributable to Bexil shareholders of $18.2 million and 977,168 shares issued and outstanding, share, up 7.8% from $17.29 per share a year earlier.

2017 Annual Meeting of Stockholders

Bexil announced today that its 2017 annual meeting of stockholders will be held at 11 Hanover Square, 12th Floor, New York, New York on June 15, 2017 at 11:30 a.m., local time. Stockholders of record at the close of business on April 17, 2017 are entitled to receive notice of and to vote at the meeting. After the formal business of the meeting is concluded, company executives will make a presentation of financial results and business developments, and respond to questions. To access the annual meeting and presentation by conference call, please dial 1-267-930-4000, Access Code: 509840#.

The Company’s Combined 2017 Proxy Statement and 2016 Annual Report, including audited financial statements, are available on www.Bexil.com.

About Bexil Corporation

Bexil is a holding company engaged through subsidiaries in investment management and securities trading. To learn more about Bexil, including Rule 15c2-11 information, please visit www.Bexil.com.

Safe Harbor Note

This release contains certain “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Bexil, which may cause the Company’s actual results to be materially different from those expressed or implied by such statements. Investors should carefully consider the risks, uncertainties and other factors, together with all of the other information included in the Company’s Annual Report, at http://www.bexil.com/cautionary-language.html, and similar information. The forward-looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor’s understanding of the Company’s underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders’ equity attributable to Bexil shareholders divided by currently issued and outstanding shares.

Contact:

Thomas O’Malley
Chief Financial Officer
1-212-785-0900, ext. 267
tomalley@bexil.com
www.Bexil.com

SOURCE: Bexil Corporation

ReleaseID: 464331

Company Will Present on Wednesday, June 7, 2017 at 2:30pm PT (5:30pm ET)

MEDFORD, MA / ACCESSWIRE / May 26, 2017 / INVO Bioscience, Inc. (OTC PINK: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that management will present at the LD Micro Invitational Conference on Wednesday, June 7, 2017 at 2:30pm PT (5:30pm ET) in Track 3. The conference is being held at the Luxe Hotel in Los Angeles, California.

Management will be available for one-on-one meetings during the Conference. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or at info@lythampartners.com.

The presentation will be available on the company’s website at https://invobioscience.com/investors/.

“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”

View INVO Bioscience’s profile here: http://www.ldmicro.com/profile/IVOB

Profiles powered by LD Micro – News Compliments of ACCESSWIRE.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Lytham Partners, LLC
Robert Blum, Joseph Diaz, or Joe Dorame
(602) 889-9700
info@lythampartners.com

Invo Bioscience Contact:
Kathleen Karloff, CEO
(978) 878-9505 ext. 504
kkarloff@invobio.com

SOURCE: INVO Bioscience, Inc.

ReleaseID: 464330

Hague Enterprises backs another Denver-based company

DENVER, CO / ACCESSWIRE / May 26, 2017 / Des Hague, Co-Founder and CEO of Hague Enterprises (www.hagueenterprises.com), a Colorado-based investment and advisory firm, announced today that the firm has made an investment in OHLEsport, Inc. (www.ohlesport.com), its third investment in a Denver-based company.

“The OHLEsport team has developed a soccer skills development program that I believe every serious player will be utilizing in the future,” said Hague. “The Ohle, a revolutionary stationary training aid, together with the virtual learning tool offers endless applications for continuously improving every player. That the company is committed to giving back to the communities it serves was a big factor for Hague Enterprises making the investment,” concluded Hague.

“From our side, Des’ leadership history of growing sales and market cap brought us exactly what we need at this time. We are thrilled to have someone of Des’ caliber invest in our firm and help guide us as we grow our business,” stated Robert Ohle, Founding Partner of OHLEsport and inventor of The Ohle.

About Hague Enterprises

Hague Enterprises, LLC. is a Colorado-based advisory and investment company, focused in multiple sectors. The firm provides business advisory services, expansion, start-up and turn around venture capital investment opportunities, executive mentorship, consulting and leadership development programs led by the firm’s preeminent business thought leaders.

About OHLEsport

Colorado-based OHLEsport, Inc. is dedicated to the advanced training of soccer enthusiasts. After years of development, OHLEsport launched The Ohle, the ultimate soccer development program, that helps every soccer player to develop the ‘first touch’, which is the most important part of any soccer player’s skills. In the past, the first touch on the soccer ball was very time consuming and a difficult skill to teach. Now with the Ohle, you can teach proper passing techniques, accurate traps and quick touch moves along with team drills.

For more information, visit: https://www.crunchbase.com/organization/aegis-enterprises-llc#/entity, www.deshague.com and www.deshaguenews.com.

Des Hague – LinkedIn: https://www.linkedin.com/in/deshague/

Contact Information:

Hague Enterprises
http://www.HagueEnterprises.com
deshague@aegisenterprisesllc.com

SOURCE: Hague Enterprises

ReleaseID: 464328